GlassScriptPhysician profile
Teresa Payne
NPI 1295106037
$13,533.48
in general payments reported to CMS, 2019-2025
28 companies · $3,429 in 2025
The $3,429 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,110 · 2022: $1,712 · 2023: $2,536 · 2024: $3,746 · 2025: $3,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,499 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,498.70 |
| Education | $212.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,518.90 | 2021-2025 | Enbrel, Otezla, Krystexxa |
| Janssen Biotech, INC. | $1,600.44 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,566.87 | 2021-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $959.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $948.14 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $791.93 | 2021-2025 | |
| Glaxosmithkline, LLC. | $788.88 | 2021-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $734.38 | 2021-2025 | Lupkynis |
| Pfizer INC. | $573.16 | 2021-2025 | |
| Lilly USA, LLC | $560.14 | 2021-2024 | Taltz, Zepbound |
| Ani Pharmaceuticals, INC. | $551.78 | 2022-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $334.44 | 2021-2025 | Tymlos |
| Horizon Therapeutics Plc | $250.06 | 2021-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $246.08 | 2021-2025 | Orencia |
| Genzyme Corporation | $224.72 | 2021-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $153.64 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.64 | 2021-2024 | Cyltezo |
| Sandoz INC. | $96.15 | 2024-2025 | Hyrimoz, Jubbonti |
| Organon LLC | $91.74 | 2024 | |
| Scilex Pharmaceuticals INC. | $88.13 | 2024 | |
| Genentech USA, INC. | $85.29 | 2023-2025 | Actemra |
| Alexion Pharmaceuticals, INC. | $82.41 | 2024-2025 | Strensiq |
| Mallinckrodt Hospital Products INC. | $35.58 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $33.39 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $29.39 | 2023 | Arcalyst |
| Jazz Pharmaceuticals INC. | $24.51 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $22.60 | 2023 | Opsumit |
| Antares Pharma, INC. | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teresa Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.